544 692
References
[1] Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on
prostate cancer. Part II: treatment of advanced, relapsing, and
castration-resistant prostate cancer. Eur Urol 2014;65:467–79.
http://dx.doi.org/10.1016/j.eururo.2013.11.002.
[2]
Heidenreich A, Chowdhury S, Klotz L, et al. Impact of enzalutamide compared with bicalutamide on quality of life in men with meta- static castration-resistant prostate cancer: additional analyses from the TERRAIN randomised clinical trial. Eur Urol 2017;71:534–42.[3] Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of
enzalutamide versus bicalutamide for patients with metastatic
prostate cancer (TERRAIN): a randomised, double-blind, phase
2 study. Lancet Oncol 2016;17:153–63.
http://dx.doi.org/10. 1016/S1470-2045(15)00518-5.
[4] Thomsen FB, Brasso K, Christensen IJ, et al. Survival benefit of early
androgen receptor inhibitor therapy in locally advanced prostate
cancer: long-term follow-up of the SPCG-6 study. Eur J Cancer
2015;51:1283–92
. http://dx.doi.org/10.1016/j.ejca.2015.03.021.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 5 4 3 – 5 4 4
544